1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Fungal Infections – Pipeline Review, H1 2013

Fungal Infections – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 163 pages

Fungal Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Fungal Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Fungal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fungal Infections. Fungal Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Fungal Infections.
- A review of the Fungal Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fungal Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Fungal Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fungal Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Fungal Infections - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Fungal Infections Overview 9
Therapeutics Development 10
Therapeutics Development 10
An Overview of Pipeline Products for Fungal Infections 10
Fungal Infections Therapeutics under Development by Companies 12
Fungal Infections Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Fungal Infections Therapeutics - Products under Development by Companies 21
Fungal Infections Therapeutics - Products under Investigation by Universities/Institutes 25
Companies Involved in Fungal Infections Therapeutics Development 26
Valeant Pharmaceuticals International 26
AstraZeneca PLC 27
Eli Lilly and Company 28
Merck and Co., Inc. 29
Vectura Group plc 30
Rib-X Pharmaceuticals, Inc. 31
Samyang Corporation 32
Quinnova Pharmaceuticals, Inc. 33
Daewoong Pharmaceutical Co., Ltd. 34
Eisai Co., Ltd. 35
Toyama Chemical Co. Ltd 36
Helix BioMedix, Inc. 37
Lixte Biotechnology Holdings, Inc. 38
MethylGene Inc 39
BioDiem Ltd 40
NovaBay Pharmaceuticals, Inc. 41
Cleveland BioLabs, Inc. 42
Pevion Biotech Ltd 43
Nissui Pharmaceutical Co., Ltd. 44
Choongwae Pharma Corp 45
PolyMedix, Inc. 46
Palau Pharma S.A 47
F2G Ltd 48
Novabiotics Ltd 49
Aegera Therapeutics Inc. 50
Anacor Pharmaceuticals, Inc. 51
Nitric Biotherapeutics, Inc. 52
Amplyx Pharmaceuticals, Inc. 53
Ferrer Internacional S.A. 54
NovaLead Pharma Pvt. Ltd. 55
Sosei Co. Ltd. 56
Globeimmune, Inc. 57
TheraCarb Inc. 58
Lee's Pharmaceutical Holdings Limited 59
Viamet Pharmaceuticals, Inc. 60
Ramot at Tel Aviv University Ltd. 61
Laboratorio Teuto Brasileiro 62
Aureogen Biosciences, Inc. 63
Pacific Beach BioSciences, Inc 64
FunZyme BioTechnologies S.A. 65
Fungal Infections - Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Combination Products 67
Assessment by Route of Administration 68
Assessment by Molecule Type 70
Drug Profiles 72
HB-1275 - Drug Profile 72
MGCD-290 - Drug Profile 73
itraconazole - Drug Profile 75
DWJ-205 - Drug Profile 76
PMX-10098 - Drug Profile 77
T-2307 - Drug Profile 78
IDP-113 - Drug Profile 79
VLF-02 - Drug Profile 80
NVC-612 - Drug Profile 81
NXL-201 - Drug Profile 82
AN-2718 - Drug Profile 83
MK-3118 - Drug Profile 84
albaconazole - Drug Profile 85
albaconazole - Drug Profile 87
arasertaconazole - Drug Profile 89
PEV-7 - Drug Profile 90
MGCD-290 + [fluconazole] - Drug Profile 92
nitric oxide - Drug Profile 94
PB-200a - Drug Profile 96
Spicaterpenoid - Drug Profile 97
econazole nitrate - Drug Profile 98
Novamycin - Drug Profile 99
VR-461 - Drug Profile 100
BSG-005 - Drug Profile 101
tolnaftate - Drug Profile 102
E-1210 - Drug Profile 103
SLP-1002 - Drug Profile 104
SLP-0907 - Drug Profile 106
SLP-0901 - Drug Profile 108
LB-201 - Drug Profile 110
miconazole - Drug Profile 111
VT-1161 - Drug Profile 112
GI-9000 - Drug Profile 113
RX-06 - Drug Profile 114
BDM-I - Drug Profile 116
Xenomycin - Drug Profile 117
VT-1598 - Drug Profile 118
VT-1129 - Drug Profile 119
JWF-1103 - Drug Profile 120
ZK-004 - Drug Profile 121
Cercosporamide - Drug Profile 122
amphotericin B - Drug Profile 123
Antifungal Program - Drug Profile 124
Vaccine for Vaginal Candidiasis - Drug Profile 125
3-(4-chlorophenyl)-4-substituted pyrazoles Compunds - Drug Profile 126
MVX-507 - Drug Profile 127
AfMGB - Drug Profile 128
HSP90 Inhibitors - Drug Profile 129
Silver-Enzyme Hybrid Cream - Drug Profile 130
AUGC-15 - Drug Profile 131
Neomaclafungins A-I - Drug Profile 132
F3 Series - Drug Profile 133
Antifungal Compounds - Drug Profile 134
SP-3025 - Drug Profile 135
IkT-061 - Drug Profile 136
Previdersin - Drug Profile 137
CWF-0711 - Drug Profile 138
Fungal Infections Therapeutics - Drug Profile Updates 139
Fungal Infections Therapeutics - Discontinued Products 145
Fungal Infections Therapeutics - Dormant Products 146
Fungal Infections - Product Development Milestones 150
Featured News and Press Releases 150
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
Contact Us 159
Disclaimer 159



List of Tables

Number of Products Under Development for Fungal Infections, H1 2013 14
Products under Development for Fungal Infections - Comparative Analysis, H1 2013 15
Number of Products under Development by Companies, H1 2013 17
Number of Products under Development by Companies, H1 2013 (Contd..1) 18
Number of Products under Development by Companies, H1 2013 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2013 20
Comparative Analysis by Late Stage Development, H1 2013 21
Comparative Analysis by Mid Clinical Stage Development, H1 2013 22
Comparative Analysis by Early Clinical Stage Development, H1 2013 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 24
Products under Development by Companies, H1 2013 25
Products under Development by Companies, H1 2013 (Contd..1) 26
Products under Development by Companies, H1 2013 (Contd..2) 27
Products under Development by Companies, H1 2013 (Contd..3) 28
Products under Investigation by Universities/Institutes, H1 2013 29
Valeant Pharmaceuticals International, H1 2013 30
AstraZeneca PLC, H1 2013 31
Eli Lilly and Company, H1 2013 32
Merck and Co., Inc., H1 2013 33
Vectura Group plc, H1 2013 34
Rib-X Pharmaceuticals, Inc., H1 2013 35
Samyang Corporation, H1 2013 36
Quinnova Pharmaceuticals, Inc., H1 2013 37
Daewoong Pharmaceutical Co., Ltd., H1 2013 38
Eisai Co., Ltd., H1 2013 39
Toyama Chemical Co. Ltd, H1 2013 40
Helix BioMedix, Inc., H1 2013 41
Lixte Biotechnology Holdings, Inc., H1 2013 42
MethylGene Inc, H1 2013 43
BioDiem Ltd, H1 2013 44
NovaBay Pharmaceuticals, Inc., H1 2013 45
Cleveland BioLabs, Inc., H1 2013 46
Pevion Biotech Ltd, H1 2013 47
Nissui Pharmaceutical Co., Ltd., H1 2013 48
Choongwae Pharma Corp, H1 2013 49
PolyMedix, Inc., H1 2013 50
Palau Pharma S.A, H1 2013 51
F2G Ltd, H1 2013 52
Novabiotics Ltd, H1 2013 53
Aegera Therapeutics Inc., H1 2013 54
Anacor Pharmaceuticals, Inc., H1 2013 55
Nitric Biotherapeutics, Inc., H1 2013 56
Amplyx Pharmaceuticals, Inc., H1 2013 57
Ferrer Internacional S.A., H1 2013 58
NovaLead Pharma Pvt. Ltd., H1 2013 59
Sosei Co. Ltd., H1 2013 60
Globeimmune, Inc., H1 2013 61
TheraCarb Inc., H1 2013 62
Lee's Pharmaceutical Holdings Limited, H1 2013 63
Viamet Pharmaceuticals, Inc., H1 2013 64
Ramot at Tel Aviv University Ltd., H1 2013 65
Laboratorio Teuto Brasileiro, H1 2013 66
Aureogen Biosciences, Inc., H1 2013 67
Pacific Beach BioSciences, Inc, H1 2013 68
FunZyme BioTechnologies S.A., H1 2013 69
Assessment by Monotherapy Products, H1 2013 70
Assessment by Combination Products, H1 2013 71
Assessment by Stage and Route of Administration, H1 2013 73
Assessment by Stage and Molecule Type, H1 2013 75
Fungal Infections Therapeutics - Drug Profile Updates 143
Fungal Infections Therapeutics - Discontinued Products 149
Fungal Infections Therapeutics - Dormant Products 150
Fungal Infections Therapeutics - Dormant Products (Contd..1) 151
Fungal Infections Therapeutics - Dormant Products (Contd..2) 152
Fungal Infections Therapeutics - Dormant Products (Contd..3) 153



List of Figures

Number of Products under Development for Fungal Infections, H1 2013 14
Products under Development for Fungal Infections - Comparative Analysis, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 20
Late Stage Products, H1 2013 21
Mid Clinical Stage Products, H1 2013 22
Early Clinical Stage Products, H1 2013 23
Discovery and Pre-Clinical Stage Products, H1 2013 24
Assessment by Monotherapy Products, H1 2013 70
Assessment by Combination Products, H1 2013 71
Assessment by Route of Administration, H1 2013 72
Assessment by Stage and Route of Administration, H1 2013 73
Assessment by Molecule Type, H1 2013 74
Assessment by Stage and Molecule Type, H1 2013 75

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global AntiFungal Agents Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 – 2022

Global AntiFungal Agents Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 – 2022

  • $ 3900
  • Industry report
  • November 2016
  • by Occams

The global antifungal agents market was estimated to grow around $10,200 million and it is expected to experience robust growth during 2016-2022.Antifungal agent is basically a drug which helps in detecting ...

Global Antifungal Agents Market Report 2016

Global Antifungal Agents Market Report 2016

  • $ 2850
  • Industry report
  • August 2016
  • by 9Dimen Research

2016 Global Antifungal Agents Report is a professional and in-depth research report on the world's major regional market conditions of the Antifungal Agents industry, focusing on the main regions (North ...

Global Terbinafine Market Research Report 2016

Global Terbinafine Market Research Report 2016

  • $ 2850
  • Industry report
  • October 2016
  • by 9Dimen Research

2016 Global Terbinafine Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Terbinafine industry, focusing on the main regions (North America, ...


Download Unlimited Documents from Trusted Public Sources

OTC Industry in the US

  • November 2016
    52 pages
  • United States  

View report >

Global Livestock Industry

  • September 2016
    4 pages
  • Livestock  

    Antiseptics  

    Food  

  • World  

    Sweden  

View report >

Therapy Market in New Zealand

  • July 2016
    24 pages
  • Therapy  

    Anti-Infective  

    Antifungal  

  • New Zealand  

View report >

Otc Markets In The Us

8 months ago

Otc Industry In Canada

11 months ago

Related Market Segments :

Antifungal

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.